Genmab — Maj 2014
-
-
Så er de online http://abstracts.asco.org/144/CatView_144_B.html
-
-
Sanofis kombo data med Revlimid er ikke mega stærke: The ORR (≥ PR), according to IMWG criteria, among 12 evaluable pts was 58 %. Responses occurred at each DL of 3mg/kg (1PR), 5mg/kg (1PR, 1 VGPR) and 10 mg/kg (1PR, 3 VGPR).
-
pt. ingen CR !!!!!!!
-
DARA+LEN+DEX has favorable safety profile with manageable toxicities in relapsed and RR MM. Encouraging early activity is seen with marked reduction in M-protein and 8/11 patients (72%) achieving PR or better. Part 2 data will be presented
-
SAR overall response rate er ikke mega god. http://abstracts.asco.org/144/AbstView_144_129808.html kun 33% ORR i patienter behandlet med over 10 mg. de har dog 11% CR i de patienter. men stadigvæk.. Dara har noget højere ORR dog lavere CR
-
http://abstracts.asco.org/144/AbstView_144_133856.html SAR ... Ja ikke skræmmende i konkurrencen
-
OMFG tjek lige Ibrutinib+Arzerra kombi data. de er outstanding: Overall response rate in CLL/SLL was 100%
-
http://abstracts.asco.org/144/AbstView_144_132436.html At study end, 52/58 responders (90%) remained progression-free with f/u of 16, 12 and 11 months for G1, 2 and 3, respectively
-
det er i fuckin 72 patienter de leverer så høj en ORR
-
det aller bedste er for mig at se at det ikke ser ud til at SAR er Dara overlegen.
-
pt. vil jeg kalde dem equal
-
deres follow up data viser kun 33% ORR i monoterapi. Daras viser 48%. De har så 11% CR hvor Dara ikke laver nogen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind